1. Scrip
  2. >>Business
  3. >>Strategy

'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy

 
• By Sten Stovall

Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.

Oncology
Roche Vows To Keep EMR Data Leader Flatiron Independent • Source: Shutterstock

Grilled by journalists and analysts during Roche's quarterly sales update about the purchase of Flatiron Health Inc., the Swiss group's CEO and pharma chief explained in detail how acquiring the oncology-focused electronic health record company will give valuable access to real-world evidence (RWE) data that Roche aims to use to better design clinical trials and outcomes, improve chances for drug reimbursement, and thus reinforce its place as a leader in oncology therapeutics.

Answering questions on April 26 while outlining its first-quarter sales performance – which saw revenue from new drugs offset erosion...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

More from Business

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?